TERT promoter mutations and their association with BRAF V600E mutation and aggressive clinicopathological characteristics of thyroid cancer. - Wikidata - wikimedia - TriplyDB

TERT promoter mutations and their association with BRAF V600E mutation and aggressive clinicopathological characteristics of thyroid cancer.

TERT promoter mutations and their association with BRAF V600E mutation and aggressive clinicopathological characteristics of thyroid cancer.

http://www.wikidata.org/entity/Q33682388

about

Cancer-Specific Telomerase Reverse Transcriptase (TERT) Promoter Mutations: Biological and Clinical Implications Transcription Regulation of the Human Telomerase Reverse Transcriptase (hTERT) Gene Selective use of sorafenib in the treatment of thyroid cancer TERT promoter mutations in thyroid cancer Mutation Profile of Well-Differentiated Thyroid Cancer in Asians Time to re-consider the meaning of BRAF V600E mutation in papillary thyroid carcinoma Personalized therapy in patients with anaplastic thyroid cancer: targeting genetic and epigenetic alterations BRAF V600E and TERT promoter mutations cooperatively identify the most aggressive papillary thyroid cancer with highest recurrence Diagnostic and prognostic TERT promoter mutations in thyroid fine-needle aspiration biopsy.BRAF activates and physically interacts with PAK to regulate cell motility 2015 American Thyroid Association Management Guidelines for Adult Patients with Thyroid Nodules and Differentiated Thyroid Cancer: The American Thyroid Association Guidelines Task Force on Thyroid Nodules and Differentiated Thyroid Cancer Integrated data analysis reveals potential drivers and pathways disrupted by DNA methylation in papillary thyroid carcinomas.Neoplasia in Cri du Chat Syndrome from Italian and German Databases.A meta-analysis of prognostic roles of molecular markers in papillary thyroid carcinoma BRAF and NRAS Mutations in Papillary Thyroid Carcinoma and Concordance in BRAF Mutations Between Primary and Corresponding Lymph Node Metastases.Association between BRAF V600E Mutation and Ultrasound Features in Papillary Thyroid Carcinoma Patients with and without Hashimoto's Thyroiditis Association of TERT promoter mutation 1,295,228 C>T with BRAF V600E mutation, older patient age, and distant metastasis in anaplastic thyroid cancer.Characterization of thyroid cancer cell lines in murine orthotopic and intracardiac metastasis models.The Risk of Relapse in Papillary Thyroid Cancer (PTC) in the Context of BRAFV600E Mutation Status and Other Prognostic Factors.GLI1 Transcription Factor Affects Tumor Aggressiveness in Patients With Papillary Thyroid Cancers.Clinical Characteristics and Prognostic Significance of TERT Promoter Mutations in Cancer: A Cohort Study and a Meta-Analysis.BRAF V600E and TERT Promoter Mutations in Papillary Thyroid Carcinoma in Chinese Patients.Cytologic, clinicopathologic, and molecular features of papillary thyroid carcinoma with prominent hobnail features: 10 case reports and systematic literature review.Expression profiles of pivotal microRNAs and targets in thyroid papillary carcinoma: an analysis of The Cancer Genome Atlas.Association of telomerase reverse transcriptase promoter mutations with clinicopathological features and prognosis of thyroid cancer: a meta-analysis.BRAF(V600E) mutation is highly prevalent in thyroid carcinomas in the young population in Fukushima: a different oncogenic profile from Chernobyl Association of TERT Promoter Mutation, But Not BRAF Mutation, With Increased Mortality in PTC.Differential Clinicopathological Risk and Prognosis of Major Papillary Thyroid Cancer Variants.Clinical utility of TERT promoter mutations and ALK rearrangement in thyroid cancer patients with a high prevalence of the BRAF V600E mutation.Low Prevalence of Somatic TERT Promoter Mutations in Classic Papillary Thyroid Carcinoma TERT Promoter Mutations and Tumor Persistence/Recurrence in Papillary Thyroid Cancer.BRAF and TERT promoter mutations in the aggressiveness of papillary thyroid carcinoma: a study of 653 patients Telomerase reverse transcriptase promoter mutations in hepatitis B virus-associated hepatocellular carcinoma.A panel of four genes accurately differentiates benign from malignant thyroid nodules.TERT promoter Mutation and Its Association with Clinicopathological Features and Prognosis of Papillary Thyroid Cancer: A Meta-analysis Activation of mutant TERT promoter by RAS-ERK signaling is a key step in malignant progression of BRAF-mutant human melanomas.TERT promoter mutations are a major indicator of recurrence and death due to papillary thyroid carcinomas.Prognostic effects of TERT promoter mutations are enhanced by coexistence with BRAF or RAS mutations and strengthen the risk prediction by the ATA or TNM staging system in differentiated thyroid cancer patients.Current Advances in Thyroid Cancer Management. Are We Ready for the Epidemic Rise of Diagnoses?Clinicopathological significance of TERT promoter mutation in papillary thyroid carcinomas: a systematic review and meta-analysis.

P2860

Q26738705-E1236798-28BE-4EF5-A67D-3D2A3892D939 Q26739925-350521E4-2736-448F-A924-51D9F84B97D6 Q26752891-9B2D22CC-AA1C-4570-AE1D-09155BA608BD Q26770808-10858FBF-C684-47ED-A12E-1C52E5E39998 Q26782322-B2D1094E-75C8-42E5-B09F-411D9A5DC75E Q26853261-2D137906-1F8F-4BE5-8EC8-7A5E3371406D Q27027491-D7F078EB-9A56-4DB0-BE84-C1BC5BC7FEE3 Q27853042-213A7CEA-EDF7-45B0-996B-3BBAD2778522 Q27853057-2B1EB04F-1956-46AA-A19F-5ABBA4672C31 Q28248127-92B69A06-1CE0-4EF2-A531-314DAF1DA584 Q30367068-665F383E-1F10-402A-9E6B-F8234EB41847 Q33629836-0828FECA-BB52-49BC-908D-C89746500C0F Q33646339-8538E196-045A-4C67-83C4-AE0E036F5105 Q33656624-90A2CD17-6F8D-43AA-84D4-F42AEB5B0A88 Q33875906-19F8F085-BD2C-4F2F-85F9-801FD65808F2 Q33884794-F73BE0D6-A121-4394-84C2-71143FA95C94 Q35441872-7E7B9CC1-EB79-4AD4-BDEA-DA48BC9E833A Q35554680-ADFADFAE-5FD5-43D3-8927-90A90A2AAC32 Q35692478-58A85D43-7515-4637-906B-042F0855B4D7 Q35857790-B7013426-63F5-4DBD-87A6-84EF94479706 Q35901458-4C5C4BF4-8EAB-4A8B-BF43-EA6BEBA32407 Q35985808-76D73E44-E623-4D55-8123-31DBE1876FBD Q36014228-1CD62D67-6B74-40FF-B21A-2D3EB48F3309 Q36015168-3BF1363F-CC1C-4F60-B70A-672882A194E3 Q36221232-C237833F-79A9-42E3-8E38-C45F62316E10 Q36301491-46B0130F-11E7-4891-BD06-BADB6638CF97 Q36339926-CD0E55F8-74D2-49FF-A03C-6B70AF9A27C4 Q36431628-97019D07-4EC7-437C-B374-1E53F14BBC16 Q36560914-AEA3124C-F11D-477E-B218-0881B573C7EB Q36716977-C77BDD7E-304C-48ED-BD3E-771E214A96DB Q37097535-F7E621EF-2518-4635-BDEB-94DEE57C144B Q37109755-80900207-43F6-4919-B88D-B6C086A9517E Q37317414-5D32F676-9BCA-46FA-A2FB-D51E978DC3EE Q37374678-4B019B86-3BBE-4910-BFD4-B8A14F2F82C1 Q37408393-43BAC927-CC04-49C1-8C7D-39D0848FB6EB Q37514988-1A9C0907-DBFD-48B8-8335-3C4B7AAFDF58 Q38383121-C9BBFC37-BD17-4E21-9B2F-988227FC7F05 Q38416278-C9A3E661-903F-4D31-99DD-3A64359F13B5 Q38614394-BCB7F667-1C84-446D-9DEF-A7C211F0CE55 Q38687220-1F83659D-1A9B-4376-B813-81ACBBD54AC1

P2860

TERT promoter mutations and their association with BRAF V600E mutation and aggressive clinicopathological characteristics of thyroid cancer.

http://www.wikidata.org/entity/Q33682388

description

2014 nî lūn-bûn

@nan

2014 թուականի Մարտին հրատարակուած գիտական յօդուած

@hyw

2014 թվականի մարտին հրատարակված գիտական հոդված

@hy

2014年の論文

@ja

2014年論文

@yue

2014年論文

@zh-hant

2014年論文

@zh-hk

2014年論文

@zh-mo

2014年論文

@zh-tw

2014年论文

@wuu

name

TERT promoter mutations and th ...... acteristics of thyroid cancer.

@ast

TERT promoter mutations and th ...... acteristics of thyroid cancer.

@en

type

label

TERT promoter mutations and th ...... acteristics of thyroid cancer.

@ast

TERT promoter mutations and th ...... acteristics of thyroid cancer.

@en

prefLabel

TERT promoter mutations and th ...... acteristics of thyroid cancer.

@ast

TERT promoter mutations and th ...... acteristics of thyroid cancer.

@en

P1433

Q33682388-A7EAC00D-B2BD-4928-93D2-B26B40264547

P1476

Q33682388-E730AF63-3F51-4442-AF42-1A2D8DF4C933

P2093

Q33682388-068AA3CF-FD29-4484-AA1D-2F27BC9D58A6

Q33682388-3CDFA577-C1BA-4D1C-BCBB-91A1A235F0AA

Q33682388-5971D4E5-3665-4BAC-9B69-7249BBFB00B7

Q33682388-737D4C04-440E-470A-8074-1482250536FB

Q33682388-7DABFB1F-4159-48F3-AC8C-AB7738304CB3

Q33682388-83A3B9F1-F7DB-412E-8574-26F5D102FFBB

Q33682388-96EE7AA3-2D12-40E1-B2FB-BAAE010F127D

Q33682388-9FBDB762-DC72-48CD-906D-BC0C60985D3E

Q33682388-A1B68AC5-956B-4C71-9ABB-495FDA152A5F

Q33682388-A80EB374-25BD-48A5-B0B9-3D868F7486CB

P2860

Q33682388-18979A79-EC63-4FFC-8B45-1B0551A3397D

Q33682388-1E1ED886-CC83-45EF-A408-6E513BF8C0A8

Q33682388-2F4A99BF-F51B-46FC-9DBE-EBE3AE209866

Q33682388-3B5F3508-B3AB-45C9-BC84-FFFC2AA9FA44

Q33682388-41301F05-C844-4D98-97EE-2889BE81ED59

Q33682388-436F576D-6A29-4B44-BD50-4DF1458EEBA8

Q33682388-49E6D313-B871-4E7A-AF9D-5734BBFFBD9D

Q33682388-529701CF-F4C8-450D-9B12-E0AC465C6DF7

Q33682388-62D8E52A-55F2-432C-AF73-2733AB46D5CD

Q33682388-63C35987-6E5D-4839-9A81-448A68369E6C

P304

Q33682388-0D2C96F9-C77E-4305-BE4C-17B1B7FC39F6

P31

Q33682388-9642546A-E2A3-4D3D-A090-09D50BD763E8

P356

Q33682388-9381EBBF-A0FB-4EB0-9E49-337F6E7F46AD

P407

Q33682388-1BA49E7F-D970-4D8E-AC32-B3B0BB824558

P433

Q33682388-67D1F263-FA11-4820-93FF-965CF0E6B5F2

P478

Q33682388-7E7A2FBA-04FD-41D2-82A7-8954FE83A9DE

P577

Q33682388-47879808-9D5C-4D66-90D3-6A65B9FD048A

P698

Q33682388-650EB48F-6EFB-49B3-8959-5046406863D4

P932

Q33682388-7D09ACE9-CB29-47A1-86A7-4243177F434C

P356

P1433

The Journal of Clinical Endocrinology and Metabolism

P1476

TERT promoter mutations and th ...... acteristics of thyroid cancer.

@en

P2093

Avaniyapuram Kannan Murugan

http://www.w3.org/2001/XMLSchema#string

Chunjun Sheng

http://www.w3.org/2001/XMLSchema#string

Guangwu Zhu

http://www.w3.org/2001/XMLSchema#string

Haixia Guan

http://www.w3.org/2001/XMLSchema#string

Hongyu Yu

http://www.w3.org/2001/XMLSchema#string

Hui Sun

http://www.w3.org/2001/XMLSchema#string

Mingzhao Xing

http://www.w3.org/2001/XMLSchema#string

Rengyun Liu

http://www.w3.org/2001/XMLSchema#string

Shen Qu

http://www.w3.org/2001/XMLSchema#string

Weiping Teng

http://www.w3.org/2001/XMLSchema#string

P2860

Global cancer statistics

Selective response of ternary complex factor Sap1a to different mitogen-activated protein kinase subgroups

Highly prevalent TERT promoter mutations in aggressive thyroid cancers.

Risk factors for thyroid cancer: an epidemiological review focused on nutritional factors

Increased epidermal tumors and increased skin wound healing in transgenic mice overexpressing the catalytic subunit of telomerase, mTERT, in basal keratinocytes.

Highly recurrent TERT promoter mutations in human melanoma

TERT promoter mutations in familial and sporadic melanoma

Telomeres and human disease: ageing, cancer and beyond

B-Raf(V600E) and thrombospondin-1 promote thyroid cancer progression

SAP1a is a nuclear target of signaling cascades involving ERKs.

P304

E1130-6

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1210/JC.2013-4048

http://www.w3.org/2001/XMLSchema#string

P407

P433

6

http://www.w3.org/2001/XMLSchema#string

P478

99

http://www.w3.org/2001/XMLSchema#string

P577

2014-03-11T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

24617711

http://www.w3.org/2001/XMLSchema#string

P932

4037723

http://www.w3.org/2001/XMLSchema#string